Nasdaq warned biotechnology company MDRNA that it doesn't meet the minimum $10 million stock valuation requirement to be listed on the market.
Nasdaq warned biotechnology company MDRNA that it doesn’t meet the minimum $10 million stock valuation requirement to be listed on the market, the firm said Monday.
The Bothell company, formerly known as Nastech Pharmaceutical, said it would provide Nasdaq by Dec. 3 with its strategy on how to meet listing requirements.
“We are confident that Nasdaq will find our plan acceptable,” said MDRNA Chief Executive Michael French in a statement.
Ángel González: 206-515-5644 or firstname.lastname@example.org
Most Read Business Stories
- 55,000 in Washington state may have to pay back thousands in jobless benefits
- 1 house, 45 offers: Homebuyers in Western Washington hard-pressed as supply remains scarce
- FAA safety engineer goes public to slam the agency's oversight of Boeing's 737 MAX
- Boeing CEO gave up millions in pay; here's what he and other top execs earned
- Jeff Bezos gets fraction of legal fees from girlfriend’s brother